The Cooper Companies, Inc. is a medical device company with a market cap of $14.4 billion, specializing in contact lenses and women’s health care products. However, its stock has underperformed the market, falling 27.4% over the past year. Despite strong Q3 earnings, the company cut its revenue guidance due to lower demand.

Analysts expect Cooper’s adjusted EPS to grow by 10.8% year-over-year. The company has a positive earnings surprise history, meeting or exceeding estimates in the last four quarters. Consensus among 17 analysts covering the stock is a “Moderate Buy,” with a slight decrease in bullish sentiment compared to three months ago.

On Nov. 14, Wells Fargo analyst Larry Biegelsen downgraded Cooper Companies to a “Hold” with a $72 price target. The mean price target of $81.88 represents a 13.4% premium to the current price, while the highest target of $96 suggests a potential 33% upside.

Read more at Yahoo Finance: Cooper Companies Stock: Analyst Estimates & Ratings